Liminal Biosciences Inc engages in clinical-stage research and commercialization of fibrosis treatments. The company operates in two segments: Small molecule therapeutics and Plasma-derived therapeutics. The Small molecule segment develops and commercializes treatments for lung, liver, and kidney conditions. The Plasma-derived segment sells proteins and specialty plasma in addition to developing a plasma treatment product. Liminal Biosciences does business in Canada, the U.K., and the U.S., and nearly all of its revenue comes from the plasma-derived therapeutics segment.
Location: Canada, Laval
Employees: 201-500
Total raised: $105M
Founded date: 1994
Investors 3
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | Thomvest V... | thomvest.c... |
| 23.07.2021 | BDC | bdc.ca/ |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.08.2021 | - | $105M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 09.08.2021 | Liminal BioSciences : Announces Sale of Priority Review Vouc... | LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMN... | marketscre... |
| 05.05.2021 | LIMINAL BIOSCIENCES INC. Liminal BioSciences : Notice of An... | Notice of Annual and Special Meeting of Shareholders and Management Information Circular April 19,... | marketscre... |